ResearcherPeking University Third HospitalNo recent work listed

Ran Lu

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 8 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2018: 2 papers

Papers 2

Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials. Co-author DOI 10.1111/dom.13177 ↗
Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0198938 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Tianpei Hong · 2 shared papers, 2018 · strength 0.17
- Paper Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized … DOI 10.1111/dom.13177 ↗
- Paper Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells. DOI 10.1371/journal.pone.0198938 ↗
Haining Wang · 1 shared paper, 2018 · strength 0.09
- Paper Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized … DOI 10.1111/dom.13177 ↗
Jingjing Zhang · 1 shared paper, 2018 · strength 0.08
- Paper Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells. DOI 10.1371/journal.pone.0198938 ↗
Rui Wei · 1 shared paper, 2018 · strength 0.08
- Paper Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells. DOI 10.1371/journal.pone.0198938 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.